Home Trade Closing Bell 2-26-19 GWPH Trading Options GW Pharma up 14.00 dollars after hours
  Previous Video BIIB 60 min charts with weekly January 6 call options 280 calls
  Next Video 3-5-19 MELI (434.14 +17.5%) Trading the calls up to 470 dollars

2-26-19 GWPH Trading Options GW Pharma up 14.00 dollars after hours

0
0
0

2-26-19 GWPH Trading Options GW Pharma up 14.00 dollars after hours
• Reports Q1 (Dec) loss of $0.20 per share, excluding non-recurring items, $0.04 better than the S&P Capital IQ Consensus of ($0.24); revenues rose 67.5% year/year to $6.7 mln vs the $5.35 mln S&P Capital IQ Consensus.
Pipeline progress
• Sativex (nabiximols)
o FDA meeting in December resulted in regulatory pathway in the U.S.
 Initial U.S. target indication: Multiple Sclerosis spasticity
 Single Phase 3 pivotal study expect to commence in Q4 2019
o U.S. development and commercialization rights wholly owned by GW
o Over 10 placebo-controlled trials already completed in other indications, representing significant U.S. lifecycle management opportunities
• CBDV
o Initial data from 5 patient expanded access program in patients with seizures and autism presented at American Epilepsy Society Annual Meeting suggest that CBDV is well tolerated and has potential as an AED/behavioral/cognitive medicine in the autism/epilepsy population
o Company sponsored IND open for 30-patient open label study in autism –
o Investigator-led 100 patient placebo-controlled trial in autism spectrum disorder to commence in H1 2019
o Open label study in Rett syndrome and seizures due to commence H1 2019

LEAVE YOUR COMMENT

Your email address will not be published. Required fields are marked *

Translate »
cycloneslider-slide